Breaking News, Collaborations & Alliances

Avid Partners with California Institute for Regenerative Medicine

CIRM-funded programs to receive access to Avid’s suite of world-class CGT CDMO services.

Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), entered into a new partnership with the California Institute for Regenerative Medicine (CIRM) Industry Resource Partner Program. The collaboration is designed to support the advancement of manufacturing of adeno-associated adenovirus (AAV), as well as other cell and gene therapy (CGT) programs within the state of California. With $5.5 billion in funding from the state of California, CIRM is accelerating world-class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world.

Under terms of the partnership, Avid has joined the CIRM Industry Resource Partner Program to provide development and CGMP manufacturing services to CIRM-funded programs. The company will assist CIRM’s partners in accelerating gene therapy development and manufacturing through its suite of CDMO services, which span process and analytical development, cell banking, virus banking, drug substance manufacturing, and fill-finish activities. CIRM-funded programs will be offered access to Avid’s services in order to reduce the timelines required to advance through clinical development. All partnership activities will be performed in Avid’s recently launched, world-class CGT CGMP manufacturing facility in Orange County, California.

“CIRM was established with a mission to provide treatments to patients with unmet medical needs through the promise of cell and gene therapy,” said Drew Brennan, general manager, viral technologies of Avid Bioservices. “As a proud California-based company, Avid Bioservices is excited to be collaborating with CIRM to help fulfill this vision through our strong development capabilities, established quality systems and proven commercial manufacturing experience in support of delivering these treatments to patients in need.”

Shyam Patel, senior director of business development and alliance management at CIRM said, “CIRM’s Industry Resource Partner Program aims to amplify its impact by partnering with industry leaders who possess the necessary resources, expertise, and experience to accelerate regenerative medicine research projects. We are thrilled to welcome Avid Bioservices to our network of partners who share our unwavering commitment to advancing transformative regenerative medicine therapies for patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters